Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 9/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794865 | 1.00 | WNT3A (0.50) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL30795276 | 0.91 | WNT3A (0.52) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL970919 | 0.91 | WNT3A (0.52) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL971761 | 0.91 | GAA (0.56) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL969480 | 0.90 | AKT1 (0.53) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL971878 | 0.90 | AKT1 (0.49) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL30824718 | 0.90 | AKT1 (0.49) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL30824698 | 0.89 | PIK3CD (0.54) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL968661 | 0.89 | AKT1 (0.52) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL973883 | 0.89 | PIK3CD (0.54) | WNT3AAKT1PIK3CDPIK3CBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298766-B1 | Pharmaceutical formulations comrpising a substituted pyridine derivative | LUNDBECK & CO AS H (DK) | 2013-09-18 | — | — | EP | claimed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | claimed |
| EP-2298766-A1 | Substituted pyridine derivatives | H. Lundbeck A/S (DK) | 2011-03-23 | — | — | EP | claimed |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-01-06 | — | — | US | claimed |
| US-7812020-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | claimed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| US-20080318953-A1 | Substituted Pyridine Derivatives | H. LUNDBECK A/S (DK) | 2008-12-25 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2298766-B1 | Pharmaceutical formulations comrpising a substituted pyridine derivative | LUNDBECK & CO AS H (DK) | 2013-09-18 | — | — | EP | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-8299071-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| EP-2298766-A1 | Substituted pyridine derivatives | H. Lundbeck A/S (DK) | 2011-03-23 | — | — | EP | disclosed |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-7812020-B2 | Substituted pyridine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-20080318953-A1 | Substituted Pyridine Derivatives | H. LUNDBECK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | WNT3A 3329/4885AKT1 4548/4885PIK3CD 979/4885 |
| US-20080318953-A1 | Substituted Pyridine Derivatives | KCNQ2, KCNQ1, KCNQ5 | WNT3A 4139/4885AKT1 4427/4885PIK3CD 1381/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | WNT3A 3682/4885AKT1 4605/4885PIK3CD 1397/4885 |
| US-20110003811-A1 | SUBSITUTED PYRIDINE DERIVATIVES | KCNQ2, KCNQ1, KCNQ5 | WNT3A 4143/4885AKT1 3936/4885PIK3CD 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.